This week, the secondary copper market showed a divergent pattern under the dual influence of improving macro expectations ...
Physical therapy is routinely recommended for knee pain attributed to a degenerative meniscal tear, but its efficacy has not ...
Elon Musk’s artificial intelligence company xAI has launched Grokipedia 0.1, positioning it as a direct rival to Wikipedia, ...
Randomized trial data support the use of either TNF or IL-17 inhibitors to treat axial spondyloarthritis, based on patient ...
EDP-323 significantly reduced mean viral load AUC by 85% and 87% in the high- and low-dose groups, respectively, compared ...
Background Smoke-free and aerosol-free households (SAFHs) reduce exposure to secondhand smoke and aerosol and support ...
Staloral® Birch Phase III Study successfully meets primary endpoint, demonstrating efficacy in children and adolescents.
PREVAIL phase III trial of gefurulimab meets its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in MG-ADL ...
Rocatinlimab shows real-world promise for moderate to severe AD, enhancing treatment efficacy and reducing steroid reliance, explains Emma Guttman-Yassky, MD, PhD.
The real-world Evoque and new TRILUMINATE findings provide an “extension” from the pivotal trials, Dharam Kumbhani says.
The DCB is meant to address long-term stent-related complications and avoid adding yet another metal layer in ISR.
Teams looking for help on the second level of their defense could make a trade at the deadline. Here's a look at where eight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback